Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) forced expiratory volume in 1 second (FEV1) area under the effect curve from time 0 to 6 weeks (AUEC[0-6wk]).


Clinical Trial Description

Run-In Period (Days -14 to Day -1): Participants were provided with single-blind placebo breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) device for twice-daily use after appropriate training and demonstration of the proper technique. Participants discontinued their current asthma therapy for the duration of the study. Treatment Period (Day 0 to Week 6): Participants were randomly assigned to treatment and device type through a qualified randomization service provider (ie, IRT). The interactive response technology (IRT) system stratified patients based on treatment at the time of screening visit, either inhaled corticosteroid (ICS) or non-corticosteroid (NCS). During the study, blinded persons were blinded to treatment (active or placebo) assigned but not device (BAI or MDI) assignment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02513160
Study type Interventional
Source Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status Completed
Phase Phase 3
Start date September 30, 2015
Completion date March 31, 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02883530 - Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study
Completed NCT02003521 - Impact of Lung Flute Therapy on Asthma N/A
Completed NCT01253603 - Efficacy, Safety, and Pharmacokinetics of QAW039 Phase 2
Completed NCT01845025 - Study of Safety of Foradil in Patients With Persistent Asthma Phase 4
Not yet recruiting NCT02053402 - Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Phase 4
Completed NCT01156844 - Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol Phase 2
Completed NCT01078688 - Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma N/A
Completed NCT02176694 - Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care N/A
Completed NCT02026336 - E-nose and Inflammatory Asthma Phenotypes N/A
Withdrawn NCT04271839 - Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients Phase 4
Active, not recruiting NCT04480242 - Asthma Research in Children and Adolescents
Completed NCT02175771 - Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Phase 3
Completed NCT01147510 - Asthma Control in Elderly Patients With Montelukast Phase 4
Completed NCT03541187 - Cockroach Immunotherapy in Children and Adolescents Phase 2
Completed NCT02040779 - A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma Phase 3
Active, not recruiting NCT05843045 - Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma N/A